慢性肾病对OAT1/3介导的肾小管分泌影响及PBPK建模与剂量调整建议
该研究汇总33种OAT1/3分泌底物的临床药动学数据,分析轻、中、重度CKD对肾清除、肾小管分泌及蛋白结合的影响。发现重度CKD时OAT1/3介导的分泌清除较GFR下降额外降低50%,而轻中度CKD的主动分泌变化与GFR成比例。建议在重度CKD的PBPK建模和OAT1/3底物剂量调整中考虑此额外50%的降低。
要点
- 重度CKD时OAT1/3介导的肾小管分泌清除较GFR下降额外降低50%。
- 轻中度CKD的主动分泌变化与GFR下降成比例,无需额外调整。
- 高蛋白结合底物在重度CKD时需实测蛋白结合,预测方程会低估fu,p升高。
核心结论
- 重度CKD时OAT1/3介导的分泌清除较GFR下降额外降低50%,应在PBPK建模和剂量调整中予以考虑。
研究设计与样本
- 汇总33种经OAT1/3肾小管分泌底物的临床药动学数据,分析轻、中、重度CKD对肾清除、肾小管分泌及蛋白结合的影响。
主要发现
- 8种高蛋白结合底物(fu,p≤0.2)在CKD中fu,p升高至2.7倍。
- 基于白蛋白变化的预测方程低估了高蛋白结合底物CKD相关的fu,p升高。
- 重度CKD时OAT1/3介导的分泌清除较GFR下降额外降低50%,轻中度CKD时主动分泌变化与GFR成比例。
关键数值与推荐
- 高蛋白结合底物fu,p范围0.0026至1.0(健康人群)。
- CKD相关fu,p升高至2.7倍(8种fu,p≤0.2的高蛋白结合底物)。
- 重度CKD时OAT1/3介导的分泌清除额外降低50%(相对于GFR下降)。
临床怎么用
- 重度CKD患者使用OAT1/3底物时,尤其主动分泌贡献高的底物,应考虑OAT1/3活性额外降低50%进行剂量调整。
- 高蛋白结合底物在重度CKD时建议实测蛋白结合,而非依赖白蛋白预测方程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is growing evidence that active tubular secretory clearance (CLs ) may not decline proportionally with the glomerular filtration rate (GFR) in chronic kidney disease (CKD), leading to the overestimation of renal clearance (CLr ) when using solely GFR to approximate disease effect on renal elimination. The clinical pharmacokinetic data of 33 renally secreted OAT1/3 substrates were collated to investigate the impact of mild, moderate, and severe CKD on CLr , tubular secretion and protein binding (fu,p ). The fu,p of the collated substrates ranged from 0.0026 to 1.0 in healthy populations; observed CKD-related increase in the fu,p (up to 2.7-fold) of 8 highly bound substrates (fu,p ≤ 0.2) was accounted for in the analysis. Use of prediction equation based on disease-related changes in albumin resulted in underprediction of the CKD-related increase in fu,p of highly bound substrates, highlighting the necessity to measure protein binding in severe CKD. The critical analysis of clinical data for 33 OAT1/3 probes established that decrease in OAT1/3 activity proportional to the changes in GFR was insufficient to recapitulate effects of severe CKD on unbound tubular secretion clearance. OAT1/3-mediated CLs was estimated to decline by an additional 50% relative to the GFR decline in severe CKD, whereas change in active secretion in mild and moderate CKD was proportional to GFR. Consideration of this additional 50% decline in OAT1/3-mediated CLs is recommended for physiologically-based pharmacokinetic models and dose adjustment of OAT1/3 substrates in severe CKD, especially for substrates with high contribution of the active secretion to CLr .
引用
- Tan SPF, Scotcher D, Rostami-Hodjegan A, et al. Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose Adjustment. Clin Pharmacol Ther. 2022. PMID: 35569107. doi:10.1002/cpt.2642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。